Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Cross talk between Wnt/{beta}-catenin and Irf8 in leukemia progression and drug resistance

[img]
Preview
PDF (Original article incl. supplement) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
4MB

Official URL:https://doi.org/10.1084/jem.20130706
PubMed:View item in PubMed
Creators Name:Scheller, M. and Schoenheit, J. and Zimmermann, K. and Leser, U. and Rosenbauer, F. and Leutz, A.
Journal Title:Journal of Experimental Medicine
Journal Abbreviation:J Exp Med
Volume:210
Number:11
Page Range:2239-2256
Date:21 October 2013
Keywords:BCR-ABL Positive Chronic Myelogenous Leukemia, Benzamides, Blast Crisis, Disease Progression, Gene Expression Profiling, Hematopoietic Stem Cells, Immunophenotyping, Interferon Regulatory Factors, Myeloid Cells, Neoplasm Drug Resistance, Neoplastic Gene Expression Regulation, Neoplastic Stem Cells, Piperazines, Pyrimidines, Side-Population Cells, Wnt Signaling Pathway, Animals, Mice
Abstract:Progression and disease relapse of chronic myeloid leukemia (CML) depends on leukemia-initiating cells (LIC) that resist treatment. Using mouse genetics and a BCR-ABL model of CML, we observed cross talk between Wnt/{beta}-catenin signaling and the interferon-regulatory factor 8 (Irf8). In normal hematopoiesis, activation of {beta}-catenin results in up-regulation of Irf8, which in turn limits oncogenic {beta}-catenin functions. Self-renewal and myeloproliferation become dependent on {beta}-catenin in Irf8-deficient animals that develop a CML-like disease. Combined Irf8 deletion and constitutive {beta}-catenin activation result in progression of CML into fatal blast crisis, elevated leukemic potential of BCR-ABL-induced LICs, and Imatinib resistance. Interestingly, activated {beta}-catenin enhances a preexisting Irf8-deficient gene signature, identifying {beta}-catenin as an amplifier of progression-specific gene regulation in the shift of CML to blast crisis. Collectively, our data uncover Irf8 as a roadblock for {beta}-catenin-driven leukemia and imply both factors as targets in combinatorial therapy.
ISSN:0022-1007
Publisher:Rockefeller University Press (U.S.A.)
Item Type:Article

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library